Qilin Pills for idiopathic oligoasthenospermia: A multi-centered randomized double-blind controlled clinical trial.
- Author:
Jia-Ming MAO
1
;
Hui JIANG
1
;
Chuan-Hang WANG
2
;
Ke-Qin NING
3
;
Ji-Hong LIU
4
;
Shu-Wen YANG
5
;
Hai-Song LI
6
;
Shao-Hu ZHOU
7
;
Zhi-Chao ZHANG
8
;
Ji-Xiu XU
9
;
Yong-Han HUANG
10
Author Information
1. Department of Urology, Peking University Third Hospital, Beijing 100191, China.
2. Department of Andrology, Beijing Sino-Japan Friendship Hospital, Beijing 100029, China.
3. Department of Andrology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, China.
4. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
5. Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
6. Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
7. Department of Urology and Andrology, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510405, China.
8. Department of Andrology, Peking University First Hospital, Beijing 100034, China.
9. Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
10. Department of Urology, Foshan First People's Hospital, Foshan, Guangdong 528000, China.
- Publication Type:Journal Article
- Keywords:
Qilin Pills;
clinical efficacy;
oligoasthenospermia;
safety
- MeSH:
Asthenozoospermia;
drug therapy;
Capsules;
Double-Blind Method;
Drugs, Chinese Herbal;
therapeutic use;
Humans;
Infertility, Male;
drug therapy;
Male;
Oligospermia;
drug therapy;
Semen Analysis;
Sperm Count;
Sperm Motility;
Treatment Outcome
- From:
National Journal of Andrology
2017;23(3):251-255
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of Qilin Pills in the treatment of oligoasthenospermia in infertile men.
METHODS:This multi-centered randomized double-blind controlled clinical trial included 216 infertile males with oligoasthenospermia, 108 in the trial group and the other 108 in the control, the former treated with Qilin Pills at the dose of 6 g tid while the latter with Wuziyanzong Pills at 6 g bid, both for 12 weeks. We examined the total sperm count, sperm motility and the count of progressively motile sperm of the patients before and at 4, 8 and 12 weeks after medication and evaluated the safety of the drug based on the adverse events and the laboratory results of blood and urine routine examinations and liver and kidney function tests.
RESULTS:Compared with the baseline, the patients in the trial group showed a significant time-dependent improvement after 4, 8 and 12 weeks of medication in sperm motility (21.75% vs 27.54%, 29.04% and 32.95%, P <0.05), total sperm count (156.27 ×106 vs 177.33, 188.18 and 205.44 ×106, P <0.05), and the count of progressively motile sperm (32.08 ×10⁶/ml vs 46.33, 50.98 and 61.10 ×10⁶/ml, P <0.05). The three parameters above were also improved in the controls, but more significantly in the trial group (P <0.05).
CONCLUSIONS:Qilin Pills can evidently improve the semen quality of oligoasthenospermia patients with no obvious adverse events.
